ITB-MED AB
559017-9429ActiveDeveloping novel antibody therapy to eliminate post-transplant immunosuppression needs.
Biotechnology Companyitb-med.com
Overview
- 10–19
- Employees
- 50–100M SEK
- Revenue
- 2015
- Founded
Description
ITB-MED is a specialized biotechnology company focused on transforming organ transplantation outcomes. The organization is developing TCD601 (siplizumab), a proprietary antagonistic CD2-directed monoclonal antibody. This novel therapy aims to achieve transplantation tolerance, potentially freeing pa...
Tags
B2BHealthTechPharmaceuticals
Keywords
AutoimmunityBiotechnologyClinical Trials